 |
|
|
| |
Sofosbuvir/Velpatasvir (S/V) For The Treatment Of HCV
Infection Among Vulnerable Inner-city (PWID) Residents:
Extending The Results Of Clinical Trial Part 2
|
| |
| |
EASL 2023 June 21-24 Vienna
S. YI1, G. TONIATO1, R. YUNG 1, D. TRUONG 1, S. SHARMA1, B. CONWAY 1,2
1. Vancouver Infectious Diseases Centre, Vancouver, Canada
2. Simon Fraser University, Burnaby, Canada
We note median age (range) 46 (20-81) years, 29%female, 56.4% genotype (GT) 1 , 21.2%cirrhotic, 84.6% active opiate users at the time of initiation of therapy. The next most commonly used drugs were amphetamines and crack-cocaine (69%, 52% respectively).
By ITT/mITT analysis, SVR rate is 85.1 % (171/201) and 95.5% (171/179) respectively. In the context of an opioid crisis with 7 documented deaths/day in the province of British Columbia, we have observed only 2 deaths in the treated study population from time of initial identification at CPC events.
|
| |
|
|
|
|
|
